AUPH Q4 2023 Earnings — Aurinia Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

AUPHAurinia Pharmaceuticals Inc.

$2B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$45M+58.6% YoY

Gross Profit

$40M88.0% margin

Operating Income

-$30M-65.8% margin

Net Income

-$27M-59.6% margin

EPS (Diluted)

$-0.19

QoQ Revenue Growth

-17.3%

Cash Flow

Operating Cash Flow

$14M

Free Cash Flow

$14M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$548M

Total Liabilities

$170M

Stockholders' Equity

$378M

Cash & Equivalents

$49M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$45M	$28M	+58.6%
Gross Profit	$40M	$27M	+46.6%
Operating Income	-$30M	-$28M	-5.6%
Net Income	-$27M	-$26M	-3.2%

Revenue Segments

Product

$42M100%